共 294 条
[1]
Ferrannini E(2017)Sodium-glucose co-transporters and their inhibition: clinical physiology Cell Metab 26 27-38
[2]
Wanner C(2016)Empagliflozin and progression of kidney disease in type 2 diabetes N Engl J Med 375 323-334
[3]
Inzucchi SE(2019)Canagliflozin and renal outcomes in type 2 diabetes and nephropathy N Engl J Med 380 2295-2306
[4]
Lachin JM(2019)Glucose control and the effect of empagliflozin on kidney outcomes in type 2 diabetes: an analysis from the EMPA-REG OUTCOME trial Am J Kidney Dis 74 713-715
[5]
Fitchett D(2016)Circadian blood pressure rhythm as a possible key target of SGLT2 inhibitors used for the treatment of Type 2 diabetes Hypert res 39 396-398
[6]
von Eynatten M(2018)Renoprotective effects of sodium-glucose cotransporter-2 inhibitors Kidney Int 94 26-39
[7]
Mattheus M(2021)Sodium/glucose cotransporter 2 inhibitors in chronic kidney disease and heart failure: ready for prime time in patients without diabetes Curr Opin Nephrol Hypertens 30 361-368
[8]
Johansen OE(2021)Effects of sodium/glucose Cotransporter 2 (SGLT2) inhibitors on cardiovascular and metabolic outcomes in patients without diabetes mellitus: a systematic review and meta-analysis of randomized-controlled trials J Amer Heart Assoc. 10 019463-593
[9]
Woerle HJ(2020)Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease (DIAMOND): a randomised, double-blind, crossover trial Lancet Diabetes Endocrinol 8 582-282
[10]
Broedl UC(2020)Rationale and protocol of the dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) randomized controlled trial Nephrol dial transplant 35 274-826